<DOC>
	<DOCNO>NCT02394834</DOCNO>
	<brief_summary>The purpose study investigate biomarkers may predictors efficacy safety treatment mFOLFOX6 + bevacizumab versus . mFOLFOX6 + panitumumab therapy patient chemotherapy-naïve unresectable advanced recurrent colorectal cancer .</brief_summary>
	<brief_title>An Exploratory Study Treatment Sensitivity Prognostic Factors Efficacy Safety Study mFOLFOX6 + Bevacizumab Versus . mFOLFOX6 + Panitumumab Therapy Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Cancer .</brief_title>
	<detailed_description>The drug test study call Panitumumab . This exploratory study investigate biomarkers may predictors efficacy safety treatment mFOLFOX6 + bevacizumab versus . mFOLFOX6 + panitumumab therapy patient chemotherapy-naïve unresectable advanced recurrent colorectal cancer.. Tumor tissue sample obtain participant enrol safety/efficacy study Panitumumab + mFOLFOX versus bevacizumab + + mFOLFOX ( PARADIGM Study ) provide consent additional study use . Mutations , amplification rearrangement predefined tumor-associated gene investigate use DNA collect tumor sample use assess RAS mutation plasma free DNA collect administration cycle 1 discontinuation protocol treatment main study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>( 1 ) Patients enrol main study personally provide write consent adequately explain content additional study ( 1 ) Patients determine investigator researcher suitable participate additional study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic colorectal cancer , Panitumumab , mFOLFOX6 , Bevacizumab</keyword>
</DOC>